JP2025508819A5 - - Google Patents

Info

Publication number
JP2025508819A5
JP2025508819A5 JP2024550128A JP2024550128A JP2025508819A5 JP 2025508819 A5 JP2025508819 A5 JP 2025508819A5 JP 2024550128 A JP2024550128 A JP 2024550128A JP 2024550128 A JP2024550128 A JP 2024550128A JP 2025508819 A5 JP2025508819 A5 JP 2025508819A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sequence
composition according
antibody
ror2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063226 external-priority patent/WO2023164618A1/en
Publication of JP2025508819A publication Critical patent/JP2025508819A/ja
Publication of JP2025508819A5 publication Critical patent/JP2025508819A5/ja
Pending legal-status Critical Current

Links

JP2024550128A 2022-02-25 2023-02-24 抗ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用 Pending JP2025508819A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313943P 2022-02-25 2022-02-25
US63/313,943 2022-02-25
PCT/US2023/063226 WO2023164618A1 (en) 2022-02-25 2023-02-24 Cancer treatment with a conditionally active anti-ror2 antibody-drug conjugate

Publications (2)

Publication Number Publication Date
JP2025508819A JP2025508819A (ja) 2025-04-10
JP2025508819A5 true JP2025508819A5 (https=) 2026-02-16

Family

ID=87766744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550128A Pending JP2025508819A (ja) 2022-02-25 2023-02-24 抗ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用

Country Status (10)

Country Link
US (1) US20250161472A1 (https=)
EP (1) EP4482870A1 (https=)
JP (1) JP2025508819A (https=)
KR (1) KR20240153580A (https=)
CN (1) CN119095877A (https=)
AU (1) AU2023226070A1 (https=)
CA (1) CA3244077A1 (https=)
MX (1) MX2024010440A (https=)
TW (1) TW202342537A (https=)
WO (1) WO2023164618A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322234A1 (en) * 2012-01-03 2014-10-30 The Board Of Trustees Of The Leland Stanford Junior University Analysis and Targeting of ROR2 in Cancer
US11673957B2 (en) * 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
SG11201806121PA (en) * 2016-01-20 2018-08-30 Scripps Research Inst Ror2 antibody compositions and related methods
PL3455261T3 (pl) * 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
WO2021102055A1 (en) * 2019-11-18 2021-05-27 The Regents Of The University Of California Anti-ror-2 antibodies and methods of use

Similar Documents

Publication Publication Date Title
US11510959B2 (en) Hydrophilic antibody-drug conjugates
JP7430643B2 (ja) カンプトテシンペプチドコンジュゲート
JP2022043354A (ja) 改善されたリガンド－薬物コンジュゲート薬物動態のためのｐｅｇ化薬物－リンカー
JP2024081670A (ja) トランスグルタミナーゼコンジュゲーション方法およびリンカー
JP2024059848A (ja) 操作された抗体化合物およびこれらの抱合体
JP2022513384A5 (https=)
RU2009114161A (ru) Антитела и фрагменты антител человека против рецептора фолата альфа для радиоиммунотерапии карциномы яичника
CN112533937A (zh) 用于结合cd38的肽配体
JP2005501514A5 (https=)
CA2431600A1 (en) Molecules with extended half-lives, compositions and uses thereof
JP2023538071A5 (https=)
JP2019524640A5 (https=)
CN111989339A (zh) 疏水性奥瑞他汀f化合物及其缀合物
JP2022540946A (ja) コンジュゲーションのためのポリペプチド複合体及びその応用
JP7356677B2 (ja) 複合体
JP2025512466A5 (https=)
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途
JP2022502431A5 (https=)
JP2025508819A5 (https=)
JP2024523290A5 (https=)
TWI903241B (zh) 一種帶有高穩定性親水連接單元的奧瑞他汀類藥物及其偶聯物
CN120957759A (zh) 具有抗肿瘤作用的化合物及其制备方法和用途
WO2025242221A1 (zh) 新型修饰侧链、其制备方法和应用
KR20250008730A (ko) Ror1-표적화 결합 분자 및 이의 용도
WO2026012480A1 (zh) 双特异性抗体和免疫偶联物及其用途